GLP-1 Medications and Acid Reflux: What the Research Shows
Do Ozempic, Wegovy, and Mounjaro cause acid reflux? Here's what cohort studies and meta-analyses show about GERD risk, why delayed stomach emptying drives it, and how to manage it.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on July 8, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
A burning behind the breastbone after dinner, a sour taste creeping up at night, a cough that won't quit — for a subset of people on Ozempic, Wegovy, or Mounjaro, acid reflux becomes an unwelcome companion to weight loss. GLP-1 medications and acid reflux share a mechanical logic that makes the pairing almost predictable: the same slowed digestion that curbs appetite also gives stomach acid more time and more reason to travel the wrong way.
The signal is now measurable, not anecdotal. Large cohort studies and randomized-trial meta-analyses agree that GLP-1 receptor agonists raise the risk of gastroesophageal reflux disease (GERD), even as they improve nearly every other metabolic marker. The effect is modest for most people and manageable for almost all, but it is real, and it deserves a clearer explanation than the shrug it usually gets at the pharmacy counter.
Here is what the research actually shows about GLP-1 medications and acid reflux: how much the risk rises, the biology behind it, which drugs and doses matter most, and what to do when heartburn shows up.
Why GLP-1 Drugs Trigger Reflux
The mechanism starts in the stomach, not the esophagus. GLP-1 receptor agonists slow the rate at which the stomach empties its contents into the small intestine — the same effect that makes meals feel smaller and hunger fade. But food that lingers is food that can wash back up.
Evidence: "Once-weekly semaglutide produced a first-hour delay in gastric emptying of a standardized meal compared with placebo, with a substantially larger fraction of the meal retained in the stomach at early time points." — Hjerpsted JB, et al. Diabetes, Obesity and Metabolism. 2018;20(3):610–619. DOI: 10.1111/dom.13120
A fuller stomach for longer means higher intragastric pressure and a larger reservoir of acidic content sitting just below the lower esophageal sphincter — the muscular valve that is supposed to keep everything down. When that valve relaxes, as it naturally does dozens of times a day, there is simply more material available to reflux, and it stays acidic longer because it has not moved on.
The delay is not always subtle or short-lived. In people who stay on these drugs for months, gastric retention can persist far longer than the early-hour effect suggests.
Evidence: "Among patients using semaglutide or tirzepatide for more than six months, 91.7% showed residual gastric content at upper endoscopy despite following standard fasting protocols, compared with none of those on the drugs for less than six months." — Wen J, Puglisi J, Frezza E. Cureus. 2025;17(11):e96771. DOI: 10.7759/cureus.96771
This is the same delayed-emptying physiology that, at its extreme, overlaps with gastroparesis-like symptoms in a minority of users. For most people it never reaches that severity — but even a mild, sustained slowdown tilts the odds toward reflux.
How Much Does Acid Reflux Risk Actually Rise?
Averages set the frame. The cleanest randomized-trial evidence comes from a 2025 systematic review pooling dozens of placebo-controlled trials, which isolated GERD from the broader bucket of gastrointestinal complaints.
Evidence: "GLP-1 receptor agonists probably increased the risk of gastroesophageal reflux disease, with a relative risk of 2.19 (95% CI, 1.48–3.25), corresponding to approximately 4 more cases per 1,000 people compared with placebo." — Gastroenterology systematic review and meta-analysis. 2025. DOI: 10.1053/j.gastro.2025.06.003
A relative risk more than double sounds alarming until the absolute numbers land: roughly four extra cases per thousand treated. Reflux is common at baseline, so a large relative increase still translates to a small individual bump for most users. Real-world cohort data, which capture longer follow-up and everyday prescribing, land in the same territory.
Evidence: "In an active-comparator cohort of 24,708 GLP-1 receptor agonist users versus 89,096 SGLT-2 inhibitor users with type 2 diabetes, GLP-1 use was associated with a 27% higher risk of GERD (risk ratio 1.27; 95% CI, 1.14–1.42) and a 55% higher risk of GERD complications over a median 3 years." — Noh Y, et al. Annals of Internal Medicine. 2025;178(9):1268–1278. DOI: 10.7326/ANNALS-24-03420
Two points are worth holding together. First, the risk is consistent across trial and real-world settings — this is not a fluke of one dataset. Second, the complication risk (erosive disease, strictures, bleeding) rose more sharply than uncomplicated reflux, which is the part clinicians watch most closely.
GERD Risk Across Study Types
| Evidence source | Comparison | Effect on GERD | Absolute impact |
|---|---|---|---|
| RCT meta-analysis (2025) | GLP-1 vs placebo | RR 2.19 (1.48–3.25) | ~4 more per 1,000 |
| Cohort, T2D (2025) | GLP-1 vs SGLT-2i | RR 1.27 (1.14–1.42) | 0.7 more per 100 |
| Cohort, complications (2025) | GLP-1 vs SGLT-2i | RR 1.55 (1.12–2.29) | 0.8 more per 1,000 |
These are group averages, and the spread matters. People with pre-existing reflux, a hiatal hernia, or obesity-related pressure on the stomach start closer to the edge and are more likely to feel a change.
Which Drugs and Doses Matter Most
Not every GLP-1 medication carries the same reflux weight, and the difference tracks with how strongly and how long each drug slows the gut.
Duration of Action
Long-acting agents that keep the receptor switched on around the clock — once-weekly semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — sustain gastric slowing continuously. Short-acting agents produce a more transient effect. Continuous receptor engagement is exactly what delivers steady appetite control, but it also means the stomach rarely returns to its baseline emptying speed between doses.
Titration Speed
Reflux, like nausea, tends to peak during dose escalation and settle as the gut adapts. The 4-hour gastric delay is most pronounced at higher doses and earlier in treatment.
Evidence: "Semaglutide significantly delayed 4-hour gastric emptying of a solid meal versus placebo in a randomized controlled trial, with greater retention measured by scintigraphic imaging." — Jensterle M, et al. Diabetes, Obesity and Metabolism. 2023;25(4):975–984. DOI: 10.1111/dom.14944
The practical read: a slower, more patient titration usually blunts reflux the same way it blunts nausea. Many of the same tactics that help with managing nausea on GLP-1 drugs — smaller meals, staying upright after eating, avoiding large fatty dinners — directly reduce reflux, because both symptoms share the delayed-emptying root.
How to Manage GLP-1-Related Reflux
Most reflux on these medications responds to the same measures that work for ordinary GERD, layered on top of dose adjustments unique to the drug class.
Behavioral and Dietary Steps
- Shrink and space meals. A smaller volume in a slow-emptying stomach means less pressure against the valve. Stopping at comfortable fullness matters more here than on any other medication.
- Stay vertical after eating. Avoid lying down for at least 2–3 hours after a meal; gravity does real work when emptying is slow.
- Trim the usual triggers. Late large dinners, high-fat meals, alcohol, and caffeine all worsen reflux and slow emptying further.
- Elevate the head of the bed for nighttime symptoms rather than propping up with pillows, which can bend the torso and raise abdominal pressure.
Medical Options
Over-the-counter antacids and H2 blockers handle mild, occasional symptoms. Persistent or nighttime reflux often warrants a proton pump inhibitor, which clinicians can prescribe alongside the GLP-1 without interaction concerns. If symptoms are severe, escalating slowly, or accompanied by trouble swallowing, weight loss beyond what's expected, or vomiting, that warrants evaluation — persistent gastric retention is also the reason GLP-1 drugs require special planning before surgery or endoscopy.
That perioperative concern reflects formal guidance on the delayed-emptying effect.
Evidence: "An individualized approach is advised for patients on GLP-1 receptor agonists undergoing endoscopy, guided by the presence of upper gastrointestinal symptoms rather than blanket discontinuation." — Hashash JG, et al. AGA Rapid Clinical Practice Update. Clinical Gastroenterology and Hepatology. 2024;22(4):705–707. DOI: 10.1016/j.cgh.2023.11.002
If reflux stays disruptive despite these steps, options include slowing or pausing titration, holding at a lower dose, or in some cases switching agents — decisions best made with the prescribing clinician rather than by stopping abruptly.
Key Takeaways
GLP-1 medications raise the risk of acid reflux by slowing how fast the stomach empties — the same effect that quiets appetite. Randomized trials put the relative risk at roughly double placebo, while real-world cohorts show about a 27% increase, both translating to a small absolute rise for most people. The risk clusters early in treatment and during dose escalation, weighs heaviest on those with pre-existing reflux, and tracks with the sustained gastric slowing of long-acting drugs.
The reassuring frame: reflux on these medications is common enough to expect but mild enough to manage in the large majority. Smaller meals, staying upright after eating, patient titration, and standard acid-suppressing medication resolve most cases. The symptoms worth escalating — trouble swallowing, severe or worsening pain, vomiting — are the exceptions, and they signal a conversation with a clinician rather than a reason to abandon a drug that is doing the rest of its job well.
References
- Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Annals of Internal Medicine. 2025;178(9):1268–1278. DOI: 10.7326/ANNALS-24-03420
- Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025. DOI: 10.1053/j.gastro.2025.06.003
- Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018;20(3):610–619. DOI: 10.1111/dom.13120
- Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Janež A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. 2023;25(4):975–984. DOI: 10.1111/dom.14944
- Wen J, Puglisi J, Frezza E. Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy. Cureus. 2025;17(11):e96771. DOI: 10.7759/cureus.96771
- Hashash JG, Thompson CC, Wang AY, et al. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. Clinical Gastroenterology and Hepatology. 2024;22(4):705–707. DOI: 10.1016/j.cgh.2023.11.002
Last updated: 2026-07-08 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.